secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031881
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth
--------------------------------------------------------------------------------

- Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.
- COVID-19 testing revenue zero (126K tests in prior year); overall gross margin negative 19.2%.
- Pharmaloz projects $14-16M revenue and >$5M pre-tax profit over next 12 months; exploring potential sale.
- Nebula Genomics launching revamped DTC product 'DNA Complete' with influencer marketing campaign.
- Cash and equivalents $2.4M; working capital $16.1M; expects significant sequential revenue growth in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/0001493152-24-031881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer